

Supplemental Table. Maternal and Infant Characteristics by Infant HIV Infection Status

Characteristic	Total (N=2123)	PHIV+ (N=9)	PHEU (N=1666)	PHEU/ Indeterminate/ Missing (N=2114)
Maternal Perinatal HIV-infection, N (%)	232 (11)	2 (22)	184 (11)	230 (11)
Missing, N (%)	245 (12)	1 (11)	90 (5)	244 (12)
Maternal age at delivery (years), Median (IQR)	28.4 (23.8, 33.1)	24.3 (23.0, 30.9)	28.5 (23.8, 33.2)	28.4 (23.8, 33.1)
Missing, N (%)	81 (4)	0	7 (0)	81 (4)
Year of delivery, Median (IQR)	2011 (2009, 2013)	2010 (2009, 2014)	2011 (2009, 2013)	2011 (2009, 2013)
Trimester of first prenatal care visit				
1	1039 (49)	6 (67)	878 (53)	1033 (49)
2	447 (21)	1 (11)	347 (21)	446 (21)
3	55 (3)	1 (11)	40 (2)	54 (3)
No prenatal care/Missing	582 (27)	1 (11)	401 (24)	581 (27)
1 st viral load (copies/mL) during pregnancy				
Median (IQR)	932 (50, 10630)	10028 (5050, 60600)	954 (50, 9810)	922 (50, 10376)
>1000 copies/mL, N (%)	1034 (49)	7 (78)	816 (49)	1027 (49)
Missing, N (%)	34 (2)	0	20 (1)	34 (2)
Last viral load (copies/mL) during pregnancy				
Median (IQR)	48 (21, 119)	14200 (500, 28310)	48 (30, 96)	48 (20, 117)
>1000 copies/mL, N (%)	241 (11)	6 (67)	176 (11)	235 (11)
Missing, N (%)	34 (2)	0	20 (1)	34 (2)
1 st CD4 (cells/mm ³) during pregnancy				
Median (IQR)	447 (284, 639)	356 (234, 387)	448 (284, 644)	448 (284, 639)
<200, N (%)	282 (13)	2 (22)	214 (13)	280 (13)
200-350, N (%)	458 (22)	2 (22)	366 (22)	456 (22)
351-500, N (%)	436 (21)	4 (44)	350 (21)	432 (20)
>500, N (%)	901 (42)	1 (11)	706 (42)	900 (43)
Missing, N (%)	44 (2)	0	28 (2)	44 (2)

Characteristic	Total (N=2123)	PHIV+ (N=9)	PHEU (N=1666)	PHEU/ Indeterminate/ Missing (N=2114)
Last CD4 (cells/mm ³) during pregnancy				
Median (IQR)	485 (332, 662)	360 (257, 432)	484 (334, 664)	485 (333, 662)
<200, N (%)	208 (10)	1 (11)	154 (9)	207 (10)
200-350, N (%)	358 (17)	3 (33)	288 (17)	355 (17)
351-500, N (%)	526 (25)	4 (44)	418 (25)	522 (25)
>500, N (%)	985 (46)	1 (11)	776 (47)	984 (47)
Missing, N (%)	44 (2)	0	28 (2)	44 (2)
ARV regimen during pregnancy, N (%)				
None	23 (1)	0	14 (1)	23 (1)
Non-cART	12 (1)	0	7 (0)	12 (1)
cART with only NRTIs	157 (7)	0	123 (7)	157 (7)
cART with NNRTI	160 (8)	0	122 (7)	160 (8)
cART with PI	1509 (71)	7 (78)	1209 (73)	1502 (71)
cART with EI/FI/INSTI	215 (10)	2 (22)	154 (9)	213 (10)
Missing	47 (2)	0	37 (2)	47 (2)
ARV use in pregnancy, N (%)				
1 st trimester	1171 (55)	6 (67)	943 (57)	1165 (55)
2 nd trimester	1921 (90)	7 (78)	1525 (92)	1914 (91)
3 rd trimester	2040 (96)	7 (78)	1607 (96)	2033 (96)
No ARV use	23 (1)	0	14 (1)	23 (1)
Missing	47 (2)	0	37 (2)	47 (2)
ARV use during labor and delivery, N (%)				
Missing, N (%)	35 (2)	0	26 (2)	35 (2)
Gestational age starting ARV, (weeks) Median (IQR)				
	11.9 (0, 18.9)	0 (0, 17.4)	11.4 (0, 18.4)	11.9 (0, 18.9)
Duration of ARV use during pregnancy (weeks), Median				
	25.7 (18.3, 36.7)	21.9 (10.7, 26.4)	26.0 (19.0, 36.7)	25.7 (18.3, 36.7)
STD during pregnancy, N (%)				
	907 (43)	4 (44)	704 (42)	903 (43)
Type of delivery, N (%)				
Vaginal	851 (40)	4 (44)	700 (42)	847 (40)
Elective cesarean	886 (42)	5 (56)	718 (43)	881 (42)
Non-elective cesarean	301 (14)	0	239 (14)	301 (14)

Characteristic		Total (N=2123)	PHIV+ (N=9)	PHEU (N=1666)	PHEU/ Indeterminate/ Missing (N=2114)
	Missing	85 (4)	0	9 (1)	85 (4)
Infant gestational age (weeks) at delivery, N					
	<32	45 (2)	1 (11)	35 (2)	44 (2)
	32-36	348 (16)	2 (22)	279 (17)	346 (16)
	≥37	1639 (77)	6 (67)	1338 (80)	1633 (77)
	Missing	91 (4)	0	14 (1)	91 (4)
Infant race/ethnicity, N (%)					
	White/Other Non-Hispanic	123 (6)	0	95 (6)	123 (6)
	Black, Non-Hispanic	1371 (65)	6 (67)	1057 (63)	1365 (65)
	Hispanic	625 (29)	3 (33)	511 (31)	622 (29)
	Missing	4 (0)	0	3 (0)	4 (0)
Infant Sex, N (%)					
	Male	1084 (51)	2 (22)	849 (51)	1082 (51)
	Female	1038 (49)	7 (78)	816 (49)	1031 (49)
	Missing	1 (0)	0	1 (0)	1 (0)

PHIV+: perinatally HIV-infected, PHEU: perinatally HIV-exposed and uninfected, ARV: antiretroviral drug, cART: combination antiretroviral regimen, EI: entry inhibitor, FI: fusion inhibitor, INSTI: integrase inhibitor, PI: protease inhibitor, NNRTI: nucleoside reverse transcriptase inhibitor, NRTI: nucleoside/tide reverse transcriptase inhibitor, STD: sexually transmitted disease.